<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20230919021104&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20230919021104&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Tue, 19 Sep 2023 06:11:05 +0000</lastbuilddate>
<pubDate>Mon, 18 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Migraines and cardiovascular disease: mechanisms and methodological challenges</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37723319/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 18. doi: 10.1038/s41569-023-00934-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37723319/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37723319</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00934-7>10.1038/s41569-023-00934-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37723319</guid>
<pubDate>Mon, 18 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Tobias Kurth</dc:creator>
<dc:creator>Pamela M Rist</dc:creator>
<dc:date>2023-09-18</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Migraines and cardiovascular disease: mechanisms and methodological challenges</dc:title>
<dc:identifier>pmid:37723319</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00934-7</dc:identifier>
</item>
<item>
<title>The Role of Ablation-Based Rhythm Control in the Tangled Web of Atrial Fibrillation and Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37721977/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 19;148(12):933-935. doi: 10.1161/CIRCULATIONAHA.123.065329. Epub 2023 Sep 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37721977/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37721977</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065329>10.1161/CIRCULATIONAHA.123.065329</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37721977</guid>
<pubDate>Mon, 18 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Ratika Parkash</dc:creator>
<dc:creator>Eileen O'Meara</dc:creator>
<dc:creator>Anthony S L Tang</dc:creator>
<dc:date>2023-09-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Role of Ablation-Based Rhythm Control in the Tangled Web of Atrial Fibrillation and Heart Failure</dc:title>
<dc:identifier>pmid:37721977</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065329</dc:identifier>
</item>
<item>
<title>Letter by Figliozzi et al Regarding Article, "The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37721976/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 19;148(12):978-979. doi: 10.1161/CIRCULATIONAHA.123.064780. Epub 2023 Sep 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37721976/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37721976</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064780>10.1161/CIRCULATIONAHA.123.064780</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37721976</guid>
<pubDate>Mon, 18 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Stefano Figliozzi</dc:creator>
<dc:creator>Georgios Georgiopoulos</dc:creator>
<dc:creator>Pier-Giorgio Masci</dc:creator>
<dc:date>2023-09-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Figliozzi et al Regarding Article, "The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum"</dc:title>
<dc:identifier>pmid:37721976</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064780</dc:identifier>
</item>
<item>
<title>Response by Essayagh et al to Letter Regarding Article, "The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37721975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 19;148(12):980-981. doi: 10.1161/CIRCULATIONAHA.123.065630. Epub 2023 Sep 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37721975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37721975</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065630>10.1161/CIRCULATIONAHA.123.065630</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37721975</guid>
<pubDate>Mon, 18 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Benjamin Essayagh</dc:creator>
<dc:creator>Giovanni Benfari</dc:creator>
<dc:creator>Clemence Antoine</dc:creator>
<dc:creator>Francesco Grigioni</dc:creator>
<dc:creator>Thierry Le Tourneau</dc:creator>
<dc:creator>Jean-Christian Roussel</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Nina Ajmone Marsan</dc:creator>
<dc:creator>Aniek van Wijngaarden</dc:creator>
<dc:creator>Christophe Tribouilloy</dc:creator>
<dc:creator>Dan Rusinaru</dc:creator>
<dc:creator>Aviram Hochstadt</dc:creator>
<dc:creator>Yan Topilsky</dc:creator>
<dc:creator>Prabin Thapa</dc:creator>
<dc:creator>Hector I Michelena</dc:creator>
<dc:creator>Maurice Enriquez-Sarano</dc:creator>
<dc:date>2023-09-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Essayagh et al to Letter Regarding Article, "The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum"</dc:title>
<dc:identifier>pmid:37721975</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065630</dc:identifier>
</item>
<item>
<title>DNA Damage and Nuclear Morphological Changes in Cardiac Hypertrophy Are Mediated by SNRK Through Actin Depolymerization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37721051/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These results indicate that SNRK is a key player in cardiac hypertrophy and DNA damage through its interaction with DSTN. This interaction fine-tunes actin polymerization to reduce DDR and maintain proper cardiomyocyte nuclear shape and morphology.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 18. doi: 10.1161/CIRCULATIONAHA.123.066002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Proper nuclear organization is critical for cardiomyocyte function, because global structural remodeling of nuclear morphology and chromatin structure underpins the development and progression of cardiovascular disease. Previous reports have implicated a role for DNA damage in cardiac hypertrophy; however, the mechanism for this process is not well delineated. AMPK (AMP-activated protein kinase) family of proteins regulates metabolism and DNA damage response (DDR). Here, we examine whether a member of this family, SNRK (SNF1-related kinase), which plays a role in cardiac metabolism, is also involved in hypertrophic remodeling through changes in DDR and structural properties of the nucleus.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We subjected cardiac-specific <i>Snrk</i><sup>-/-</sup> mice to transaortic banding to assess the effect on cardiac function and DDR. In parallel, we modulated SNRK in vitro and assessed its effects on DDR and nuclear parameters. We also used phosphoproteomics to identify novel proteins that are phosphorylated by SNRK. Last, coimmunoprecipitation was used to verify Destrin (DSTN) as the binding partner of SNRK that modulates its effects on the nucleus and DDR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cardiac-specific <i>Snrk</i><sup>-/-</sup> mice display worse cardiac function and cardiac hypertrophy in response to transaortic banding, and an increase in DDR marker pH2AX (phospho-histone 2AX) in their hearts. In addition, in vitro <i>Snrk</i> knockdown results in increased DNA damage and chromatin compaction, along with alterations in nuclear flatness and 3-dimensional volume. Phosphoproteomic studies identified a novel SNRK target, DSTN, a member of F-actin depolymerizing factor proteins that directly bind to and depolymerize F-actin. SNRK binds to DSTN, and DSTN downregulation reverses excess DNA damage and changes in nuclear parameters, in addition to cellular hypertrophy, with SNRK knockdown. We also demonstrate that SNRK knockdown promotes excessive actin depolymerization, measured by the increased ratio of G-actin to F-actin. Last, jasplakinolide, a pharmacological stabilizer of F-actin, rescues the increased DNA damage and aberrant nuclear morphology in SNRK-downregulated cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results indicate that SNRK is a key player in cardiac hypertrophy and DNA damage through its interaction with DSTN. This interaction fine-tunes actin polymerization to reduce DDR and maintain proper cardiomyocyte nuclear shape and morphology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37721051/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37721051</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066002>10.1161/CIRCULATIONAHA.123.066002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37721051</guid>
<pubDate>Mon, 18 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Paulina Stanczyk</dc:creator>
<dc:creator>Yuki Tatekoshi</dc:creator>
<dc:creator>Jason S Shapiro</dc:creator>
<dc:creator>Krithika Nayudu</dc:creator>
<dc:creator>Yihan Chen</dc:creator>
<dc:creator>Zachary Zilber</dc:creator>
<dc:creator>Matthew Schipma</dc:creator>
<dc:creator>Adam De Jesus</dc:creator>
<dc:creator>Amir Mahmoodzadeh</dc:creator>
<dc:creator>Ashley Akrami</dc:creator>
<dc:creator>Hsiang-Chun Chang</dc:creator>
<dc:creator>Hossein Ardehali</dc:creator>
<dc:date>2023-09-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>DNA Damage and Nuclear Morphological Changes in Cardiac Hypertrophy Are Mediated by SNRK Through Actin Depolymerization</dc:title>
<dc:identifier>pmid:37721051</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066002</dc:identifier>
</item>
<item>
<title>Mental Health Conditions Among Children and Adolescents With Congenital Heart Disease: A Danish Population-Based Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37721036/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: More than one-third of children with CHD were diagnosed or treated for a mental health condition by 18 years of age. Mental health conditions began early in life and were most prominent among males and children with severe or single-ventricle heart disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 18. doi: 10.1161/CIRCULATIONAHA.123.064705. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite the known mental health burden among children with congenital heart disease (CHD), the literature is constrained by a lack of comparison cohorts and population-based follow-up data. We examined the incidence of mental health conditions among children with CHD, relative to 3 comparison cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This population-based cohort study identified all children with CHD (&lt;18 years of age; n=16 473) in Denmark from 1996 to 2017, through linkage of individual-level data across national registries. This allowed for complete follow-up of the population. Comparison cohorts included children from the general population (n=162 204), siblings of children with CHD (n=20 079), and children with non-CHD major congenital anomalies (n=47 799). Mental health conditions were identified using inpatient and outpatient hospital discharge codes, prescription data, and data on use of community-based psychology, psychiatry, and psychotherapy services. We computed cumulative incidence by 18 years of age, incidence rates, and adjusted hazard ratios (aHRs) using Cox regression. aHRs accounted for sex, year of CHD diagnosis, parental mental health, and socioeconomic status. All estimates were stratified by age, sex, and CHD complexity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The cumulative incidence of mental health conditions by 18 years of age in the CHD cohort was 35.1% (95% CI, 34.0%-36.1%), corresponding to aHRs of 1.64 (95% CI, 1.58-1.71), 1.41 (95% CI, 1.30-1.52), and 1.02 (95% CI, 0.98-1.07) compared with the general population, sibling, and major congenital anomaly cohorts, respectively. Mental health incidence rates showed prominent peaks in early childhood and adolescence. Males and children with severe or single-ventricle CHD demonstrated higher incidence rates of mental health conditions relative to females and children with mild or moderate CHD, respectively. Compared with the general population and sibling cohorts, incidence rates and aHRs in the CHD cohort were highest for severe stress reactions, attention deficit/hyperactivity disorder, intellectual disability, and autism spectrum disorder. Compared with children in the major congenital anomaly cohort, the aHRs were close to 1.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: More than one-third of children with CHD were diagnosed or treated for a mental health condition by 18 years of age. Mental health conditions began early in life and were most prominent among males and children with severe or single-ventricle heart disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37721036/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37721036</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064705>10.1161/CIRCULATIONAHA.123.064705</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37721036</guid>
<pubDate>Mon, 18 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Kimberley G Miles</dc:creator>
<dc:creator>Dóra Körmendiné Farkas</dc:creator>
<dc:creator>Kristina Laugesen</dc:creator>
<dc:creator>Henrik Toft Sørensen</dc:creator>
<dc:creator>Nadine A Kasparian</dc:creator>
<dc:creator>Nicolas Madsen</dc:creator>
<dc:date>2023-09-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Mental Health Conditions Among Children and Adolescents With Congenital Heart Disease: A Danish Population-Based Cohort Study</dc:title>
<dc:identifier>pmid:37721036</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064705</dc:identifier>
</item>
<item>
<title>2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37721023/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>In this focused update, the American Heart Association provides updated guidance for resuscitation of patients with cardiac arrest, respiratory arrest, and refractory shock due to poisoning. Based on structured evidence reviews, guidelines are provided for the treatment of critical poisoning from benzodiazepines, β-adrenergic receptor antagonists (also known as β-blockers), L-type calcium channel antagonists (commonly called calcium channel blockers), cocaine, cyanide, digoxin and related...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 18. doi: 10.1161/CIR.0000000000001161. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In this focused update, the American Heart Association provides updated guidance for resuscitation of patients with cardiac arrest, respiratory arrest, and refractory shock due to poisoning. Based on structured evidence reviews, guidelines are provided for the treatment of critical poisoning from benzodiazepines, β-adrenergic receptor antagonists (also known as β-blockers), L-type calcium channel antagonists (commonly called calcium channel blockers), cocaine, cyanide, digoxin and related cardiac glycosides, local anesthetics, methemoglobinemia, opioids, organophosphates and carbamates, sodium channel antagonists (also called sodium channel blockers), and sympathomimetics. Recommendations are also provided for the use of venoarterial extracorporeal membrane oxygenation. These guidelines discuss the role of atropine, benzodiazepines, calcium, digoxin-specific immune antibody fragments, electrical pacing, flumazenil, glucagon, hemodialysis, hydroxocobalamin, hyperbaric oxygen, insulin, intravenous lipid emulsion, lidocaine, methylene blue, naloxone, pralidoxime, sodium bicarbonate, sodium nitrite, sodium thiosulfate, vasodilators, and vasopressors for the management of specific critical poisonings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37721023/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37721023</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001161>10.1161/CIR.0000000000001161</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37721023</guid>
<pubDate>Mon, 18 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Eric J Lavonas</dc:creator>
<dc:creator>Peter D Akpunonu</dc:creator>
<dc:creator>Ann M Arens</dc:creator>
<dc:creator>Kavita M Babu</dc:creator>
<dc:creator>Dazhe Cao</dc:creator>
<dc:creator>Robert S Hoffman</dc:creator>
<dc:creator>Christopher O Hoyte</dc:creator>
<dc:creator>Maryann E Mazer-Amirshahi</dc:creator>
<dc:creator>Andrew Stolbach</dc:creator>
<dc:creator>Maude St-Onge</dc:creator>
<dc:creator>Trevonne M Thompson</dc:creator>
<dc:creator>George Sam Wang</dc:creator>
<dc:creator>Amber V Hoover</dc:creator>
<dc:creator>Ian R Drennan</dc:creator>
<dc:creator>American Heart Association</dc:creator>
<dc:date>2023-09-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care</dc:title>
<dc:identifier>pmid:37721023</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001161</dc:identifier>
</item>
<item>
<title>Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714137/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4254-4255. doi: 10.1016/j.cell.2023.08.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714137/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37714137</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.025>10.1016/j.cell.2023.08.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714137</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Yasuyuki Hosono</dc:creator>
<dc:creator>Yashar S Niknafs</dc:creator>
<dc:creator>John R Prensner</dc:creator>
<dc:creator>Matthew K Iyer</dc:creator>
<dc:creator>Saravana M Dhanasekaran</dc:creator>
<dc:creator>Rohit Mehra</dc:creator>
<dc:creator>Sethuramasundaram Pitchiaya</dc:creator>
<dc:creator>Jean Tien</dc:creator>
<dc:creator>June Escara-Wilke</dc:creator>
<dc:creator>Anton Poliakov</dc:creator>
<dc:creator>Shih-Chun Chu</dc:creator>
<dc:creator>Sahal Saleh</dc:creator>
<dc:creator>Keerthana Sankar</dc:creator>
<dc:creator>Fengyun Su</dc:creator>
<dc:creator>Shuling Guo</dc:creator>
<dc:creator>Yuanyuan Qiao</dc:creator>
<dc:creator>Susan M Freier</dc:creator>
<dc:creator>Huynh-Hoa Bui</dc:creator>
<dc:creator>Xuhong Cao</dc:creator>
<dc:creator>Rohit Malik</dc:creator>
<dc:creator>Timothy M Johnson</dc:creator>
<dc:creator>David G Beer</dc:creator>
<dc:creator>Felix Y Feng</dc:creator>
<dc:creator>Weibin Zhou</dc:creator>
<dc:creator>Arul M Chinnaiyan</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA</dc:title>
<dc:identifier>pmid:37714137</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.025</dc:identifier>
</item>
<item>
<title>Orphan quality control shapes network dynamics and gene expression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714136/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4252-4253. doi: 10.1016/j.cell.2023.08.006.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714136/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37714136</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.006>10.1016/j.cell.2023.08.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714136</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Kevin G Mark</dc:creator>
<dc:creator>SriDurgaDevi Kolla</dc:creator>
<dc:creator>Jacob D Aguirre</dc:creator>
<dc:creator>Danielle M Garshott</dc:creator>
<dc:creator>Stefan Schmitt</dc:creator>
<dc:creator>Diane L Haakonsen</dc:creator>
<dc:creator>Christina Xu</dc:creator>
<dc:creator>Lukas Kater</dc:creator>
<dc:creator>Georg Kempf</dc:creator>
<dc:creator>Brenda Martínez-González</dc:creator>
<dc:creator>David Akopian</dc:creator>
<dc:creator>Stephanie K See</dc:creator>
<dc:creator>Nicolas H Thomä</dc:creator>
<dc:creator>Michael Rapé</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Orphan quality control shapes network dynamics and gene expression</dc:title>
<dc:identifier>pmid:37714136</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.006</dc:identifier>
</item>
<item>
<title>Modular pooled discovery of synthetic knockin sequences to program durable cell therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>Chronic stimulation can cause T cell dysfunction and limit the efficacy of cellular immunotherapies. Improved methods are required to compare large numbers of synthetic knockin (KI) sequences to reprogram cell functions. Here, we developed modular pooled KI screening (ModPoKI), an adaptable platform for modular construction of DNA KI libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4216-4234.e33. doi: 10.1016/j.cell.2023.08.013.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chronic stimulation can cause T cell dysfunction and limit the efficacy of cellular immunotherapies. Improved methods are required to compare large numbers of synthetic knockin (KI) sequences to reprogram cell functions. Here, we developed modular pooled KI screening (ModPoKI), an adaptable platform for modular construction of DNA KI libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors (SRs). Over 30 ModPoKI screens across human TCR- and CAR-T cells in diverse conditions identified a transcription factor AP4 (TFAP4) construct that enhanced fitness of chronically stimulated CAR-T cells and anti-cancer function in vitro and in vivo. ModPoKI's modularity allowed us to generate an ∼10,000-member library of TF combinations. Non-viral KI of a combined BATF-TFAP4 polycistronic construct enhanced fitness. Overexpressed BATF and TFAP4 co-occupy and regulate key gene targets to reprogram T cell function. ModPoKI facilitates the discovery of complex gene constructs to program cellular functions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37714135</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.013>10.1016/j.cell.2023.08.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714135</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Franziska Blaeschke</dc:creator>
<dc:creator>Yan Yi Chen</dc:creator>
<dc:creator>Ryan Apathy</dc:creator>
<dc:creator>Bence Daniel</dc:creator>
<dc:creator>Andy Y Chen</dc:creator>
<dc:creator>Peixin Amy Chen</dc:creator>
<dc:creator>Katalin Sandor</dc:creator>
<dc:creator>Wenxi Zhang</dc:creator>
<dc:creator>Zhongmei Li</dc:creator>
<dc:creator>Cody T Mowery</dc:creator>
<dc:creator>Tori N Yamamoto</dc:creator>
<dc:creator>William A Nyberg</dc:creator>
<dc:creator>Angela To</dc:creator>
<dc:creator>Ruby Yu</dc:creator>
<dc:creator>Raymund Bueno</dc:creator>
<dc:creator>Min Cheol Kim</dc:creator>
<dc:creator>Ralf Schmidt</dc:creator>
<dc:creator>Daniel B Goodman</dc:creator>
<dc:creator>Tobias Feuchtinger</dc:creator>
<dc:creator>Justin Eyquem</dc:creator>
<dc:creator>Chun Jimmie Ye</dc:creator>
<dc:creator>Julia Carnevale</dc:creator>
<dc:creator>Ansuman T Satpathy</dc:creator>
<dc:creator>Eric Shifrut</dc:creator>
<dc:creator>Theodore L Roth</dc:creator>
<dc:creator>Alexander Marson</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Modular pooled discovery of synthetic knockin sequences to program durable cell therapies</dc:title>
<dc:identifier>pmid:37714135</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.013</dc:identifier>
</item>
<item>
<title>Complex effects of sequence variants on lipid levels and coronary artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714134/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>Many sequence variants have additive effects on blood lipid levels and, through that, on the risk of coronary artery disease (CAD). We show that variants also have non-additive effects and interact to affect lipid levels as well as affecting variance and correlations. Variance and correlation effects are often signatures of epistasis or gene-environmental interactions. These complex effects can translate into CAD risk. For example, Trp154Ter in FUT2 protects against CAD among subjects with the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4085-4099.e15. doi: 10.1016/j.cell.2023.08.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many sequence variants have additive effects on blood lipid levels and, through that, on the risk of coronary artery disease (CAD). We show that variants also have non-additive effects and interact to affect lipid levels as well as affecting variance and correlations. Variance and correlation effects are often signatures of epistasis or gene-environmental interactions. These complex effects can translate into CAD risk. For example, Trp154Ter in FUT2 protects against CAD among subjects with the A1 blood group, whereas it associates with greater risk of CAD in others. His48Arg in ADH1B interacts with alcohol consumption to affect lipid levels and CAD. The effect of variants in TM6SF2 on blood lipids is greatest among those who never eat oily fish but absent from those who often do. This work demonstrates that variants that affect variance of quantitative traits can allow for the discovery of epistasis and interactions of variants with the environment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714134/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37714134</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.012>10.1016/j.cell.2023.08.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714134</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Audunn S Snaebjarnarson</dc:creator>
<dc:creator>Anna Helgadottir</dc:creator>
<dc:creator>Gudny A Arnadottir</dc:creator>
<dc:creator>Erna V Ivarsdottir</dc:creator>
<dc:creator>Gudmar Thorleifsson</dc:creator>
<dc:creator>Egil Ferkingstad</dc:creator>
<dc:creator>Gudmundur Einarsson</dc:creator>
<dc:creator>Gardar Sveinbjornsson</dc:creator>
<dc:creator>Thorgeir E Thorgeirsson</dc:creator>
<dc:creator>Magnus O Ulfarsson</dc:creator>
<dc:creator>Bjarni V Halldorsson</dc:creator>
<dc:creator>Isleifur Olafsson</dc:creator>
<dc:creator>Christian Erikstrup</dc:creator>
<dc:creator>Ole B Pedersen</dc:creator>
<dc:creator>Mette Nyegaard</dc:creator>
<dc:creator>Mie T Bruun</dc:creator>
<dc:creator>Henrik Ullum</dc:creator>
<dc:creator>Søren Brunak</dc:creator>
<dc:creator>Kasper Karmark Iversen</dc:creator>
<dc:creator>Alex Hoerby Christensen</dc:creator>
<dc:creator>Morten S Olesen</dc:creator>
<dc:creator>Jonas Ghouse</dc:creator>
<dc:creator>Karina Banasik</dc:creator>
<dc:creator>DBDS Genomic Consortium</dc:creator>
<dc:creator>Kirk U Knowlton</dc:creator>
<dc:creator>David O Arnar</dc:creator>
<dc:creator>Gudmundur Thorgeirsson</dc:creator>
<dc:creator>Lincoln Nadauld</dc:creator>
<dc:creator>Sisse Rye Ostrowski</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Hilma Holm</dc:creator>
<dc:creator>Patrick Sulem</dc:creator>
<dc:creator>Kari Stefansson</dc:creator>
<dc:creator>Daniel F Gudbjartsson</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Complex effects of sequence variants on lipid levels and coronary artery disease</dc:title>
<dc:identifier>pmid:37714134</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.012</dc:identifier>
</item>
<item>
<title>TGF-β signaling in health and disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>The TGF-β regulatory system plays crucial roles in the preservation of organismal integrity. TGF-β signaling controls metazoan embryo development, tissue homeostasis, and injury repair through coordinated effects on cell proliferation, phenotypic plasticity, migration, metabolic adaptation, and immune surveillance of multiple cell types in shared ecosystems. Defects of TGF-β signaling, particularly in epithelial cells, tissue fibroblasts, and immune cells, disrupt immune tolerance, promote...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4007-4037. doi: 10.1016/j.cell.2023.07.036.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The TGF-β regulatory system plays crucial roles in the preservation of organismal integrity. TGF-β signaling controls metazoan embryo development, tissue homeostasis, and injury repair through coordinated effects on cell proliferation, phenotypic plasticity, migration, metabolic adaptation, and immune surveillance of multiple cell types in shared ecosystems. Defects of TGF-β signaling, particularly in epithelial cells, tissue fibroblasts, and immune cells, disrupt immune tolerance, promote inflammation, underlie the pathogenesis of fibrosis and cancer, and contribute to the resistance of these diseases to treatment. Here, we review how TGF-β coordinates multicellular response programs in health and disease and how this knowledge can be leveraged to develop treatments for diseases of the TGF-β system.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37714133</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.036>10.1016/j.cell.2023.07.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714133</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Joan Massagué</dc:creator>
<dc:creator>Dean Sheppard</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>TGF-β signaling in health and disease</dc:title>
<dc:identifier>pmid:37714133</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.036</dc:identifier>
</item>
<item>
<title>Getting an aMPLe grasp on hematopoiesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>Hematopoiesis requires balance between self-renewal of stem cells and differentiation into mature blood cells, orchestrated by pathways such as thrombopoietin signaling. In this issue of Cell, Tsutsumi et al. report the structure of the thrombopoietin ligand-receptor complex and demonstrate the potential to decouple its roles in self-renewal and hematopoietic differentiation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4005-4006. doi: 10.1016/j.cell.2023.08.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hematopoiesis requires balance between self-renewal of stem cells and differentiation into mature blood cells, orchestrated by pathways such as thrombopoietin signaling. In this issue of Cell, Tsutsumi et al. report the structure of the thrombopoietin ligand-receptor complex and demonstrate the potential to decouple its roles in self-renewal and hematopoietic differentiation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37714132</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.015>10.1016/j.cell.2023.08.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714132</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Samantha Joubran</dc:creator>
<dc:creator>Vijay G Sankaran</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Getting an aMPLe grasp on hematopoiesis</dc:title>
<dc:identifier>pmid:37714132</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.015</dc:identifier>
</item>
<item>
<title>Looking beyond the H5 avian influenza viruses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714131/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>Avian influenza viruses continue to cross the species barrier and infect mammals. In this issue of Cell, Sun and colleagues demonstrate that viruses obtained from humans infected with an emergent avian H3N8 viruses exhibit increasing accumulation of mutations that promote respiratory droplet transmission and disease in mammals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4003-4004. doi: 10.1016/j.cell.2023.08.014.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Avian influenza viruses continue to cross the species barrier and infect mammals. In this issue of Cell, Sun and colleagues demonstrate that viruses obtained from humans infected with an emergent avian H3N8 viruses exhibit increasing accumulation of mutations that promote respiratory droplet transmission and disease in mammals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714131/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37714131</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.014>10.1016/j.cell.2023.08.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714131</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Rebekah Honce</dc:creator>
<dc:creator>Stacey Schultz-Cherry</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Looking beyond the H5 avian influenza viruses</dc:title>
<dc:identifier>pmid:37714131</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.014</dc:identifier>
</item>
<item>
<title>ANGPTL3 Deficiency and Risk of Hepatic Steatosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37712257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: ANGPTL3 deficiency related to LoF mutations in ANGPTL3, as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065866. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: ANGPTL3 (angiopoietin-like 3 protein) is a therapeutic target for reducing plasma levels of triglycerides and low-density lipoprotein cholesterol. A recent trial with vupanorsen, an antisense oligonucleotide targeting hepatic production of ANGPTL3, reported a dose-dependent increase in hepatic fat. It is unclear whether this adverse effect is due to an on-target effect of inhibiting hepatic ANGPTL3.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors recruited participants with ANGPTL3 deficiency related to <i>ANGPTL3</i> loss-of-function (LoF) mutations, along with wild-type (WT) participants from 2 previously characterized cohorts located in Campodimele, Italy, and St. Louis, MO. Magnetic resonance spectroscopy and magnetic resonance proton density fat fraction were performed to measure hepatic fat fraction and the distribution of extrahepatic fat. To estimate the causal relationship between ANGPTL3 and hepatic fat, we generated a genetic instrument of plasma ANGPTL3 levels as a surrogate for hepatic protein synthesis and performed Mendelian randomization analyses with hepatic fat in the UK Biobank study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We recruited participants with complete (n=6) or partial (n=32) ANGPTL3 deficiency related to <i>ANGPTL3</i> LoF mutations, as well as WT participants (n=92) without LoF mutations. Participants with ANGPTL3 deficiency exhibited significantly lower total cholesterol (complete deficiency, 78.5 mg/dL; partial deficiency, 172 mg/dL; WT, 188 mg/dL; <i>P</i>&lt;0.05 for both deficiency groups compared with WT), along with plasma triglycerides (complete deficiency, 26 mg/dL; partial deficiency, 79 mg/dL; WT, 88 mg/dL; <i>P</i>&lt;0.05 for both deficiency groups compared with WT) without any significant difference in hepatic fat (complete deficiency, 7.9%; partial deficiency, 6.4%; WT, 6.9%; <i>P</i>>;0.05 for both deficiency groups compared with WT) or severity of hepatic steatosis as assessed by magnetic resonance imaging. In addition, ANGPTL3 deficiency did not alter the distribution of extrahepatic fat. Results from Mendelian randomization analyses in 36 703 participants from the UK Biobank demonstrated that genetically determined ANGPTL3 plasma protein levels were causally associated with low-density lipoprotein cholesterol (<i>P</i>=1.7×10<sup>-17</sup>) and triglycerides (<i>P</i>=3.2×10<sup>-18</sup>) but not with hepatic fat (<i>P</i>=0.22).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ANGPTL3 deficiency related to LoF mutations in <i>ANGPTL3</i>, as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37712257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37712257</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065866>10.1161/CIRCULATIONAHA.123.065866</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37712257</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Laura D'Erasmo</dc:creator>
<dc:creator>Michele Di Martino</dc:creator>
<dc:creator>Thomas Neufeld</dc:creator>
<dc:creator>Tyler J Fraum</dc:creator>
<dc:creator>Chul Joo Kang</dc:creator>
<dc:creator>Kendall H Burks</dc:creator>
<dc:creator>Alessia Di Costanzo</dc:creator>
<dc:creator>Ilenia Minicocci</dc:creator>
<dc:creator>Simone Bini</dc:creator>
<dc:creator>Marianna Maranghi</dc:creator>
<dc:creator>Giovanni Pigna</dc:creator>
<dc:creator>Giancarlo Labbadia</dc:creator>
<dc:creator>Jie Zheng</dc:creator>
<dc:creator>Davide Fierro</dc:creator>
<dc:creator>Anna Montali</dc:creator>
<dc:creator>Fabrizio Ceci</dc:creator>
<dc:creator>Carlo Catalano</dc:creator>
<dc:creator>Nicholas O Davidson</dc:creator>
<dc:creator>Giuseppe Lucisano</dc:creator>
<dc:creator>Antonio Nicolucci</dc:creator>
<dc:creator>Marcello Arca</dc:creator>
<dc:creator>Nathan O Stitziel</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>ANGPTL3 Deficiency and Risk of Hepatic Steatosis</dc:title>
<dc:identifier>pmid:37712257</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065866</dc:identifier>
</item>
<item>
<title>Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37712250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Ablation of CaMKIIδ autophosphorylation by adenine base editing may offer a potential broad-based therapeutic concept for human cardiac disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065117. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiovascular diseases are the main cause of worldwide morbidity and mortality, highlighting the need for new therapeutic strategies. Autophosphorylation and subsequent overactivation of the cardiac stress-responsive enzyme CaMKIIδ (Ca<sup>2+</sup>/calmodulin-dependent protein kinase IIδ) serves as a central driver of multiple cardiac disorders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To develop a comprehensive therapy for heart failure, we used CRISPR-Cas9 adenine base editing to ablate the autophosphorylation site of CaMKIIδ. We generated mice harboring a phospho-resistant CaMKIIδ mutation in the germline and subjected these mice to severe transverse aortic constriction, a model for heart failure. Cardiac function, transcriptional changes, apoptosis, and fibrosis were assessed by echocardiography, RNA sequencing, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, and standard histology, respectively. Specificity toward <i>CaMKIIδ</i> gene editing was assessed using deep amplicon sequencing. Cellular Ca<sup>2+</sup> homeostasis was analyzed using epifluorescence microscopy in Fura-2-loaded cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Within 2 weeks after severe transverse aortic constriction surgery, 65% of all wild-type mice died, and the surviving mice showed a dramatically impaired cardiac function. In contrast to wild-type mice, CaMKIIδ phospho-resistant gene-edited mice showed a mortality rate of only 11% and exhibited a substantially improved cardiac function after severe transverse aortic constriction. Moreover, CaMKIIδ phospho-resistant mice were protected from heart failure-related aberrant changes in cardiac gene expression, myocardial apoptosis, and subsequent fibrosis, which were observed in wild-type mice after severe transverse aortic constriction. On the basis of identical mouse and human genome sequences encoding the autophosphorylation site of <i>CaMKIIδ</i>, we deployed the same editing strategy to modify this pathogenic site in human induced pluripotent stem cells. It is notable that we detected a >;2000-fold increased specificity for editing of <i>CaMKIIδ</i> compared with other <i>CaMKII</i> isoforms, which is an important safety feature. Although wild-type cardiomyocytes showed impaired Ca<sup>2+</sup> transients and an increased frequency of arrhythmias after chronic β-adrenergic stress, <i>CaMKIIδ</i>-edited cardiomyocytes were protected from these adverse responses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Ablation of CaMKIIδ autophosphorylation by adenine base editing may offer a potential broad-based therapeutic concept for human cardiac disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37712250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37712250</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065117>10.1161/CIRCULATIONAHA.123.065117</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37712250</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Simon Lebek</dc:creator>
<dc:creator>Xurde M Caravia</dc:creator>
<dc:creator>Francesco Chemello</dc:creator>
<dc:creator>Wei Tan</dc:creator>
<dc:creator>John R McAnally</dc:creator>
<dc:creator>Kenian Chen</dc:creator>
<dc:creator>Lin Xu</dc:creator>
<dc:creator>Ning Liu</dc:creator>
<dc:creator>Rhonda Bassel-Duby</dc:creator>
<dc:creator>Eric N Olson</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice</dc:title>
<dc:identifier>pmid:37712250</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065117</dc:identifier>
</item>
<item>
<title>Semaglutide is beneficial in patients with HFpEF and obesity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37709935/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 14. doi: 10.1038/s41569-023-00935-6. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37709935/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37709935</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00935-6>10.1038/s41569-023-00935-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37709935</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-09-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Semaglutide is beneficial in patients with HFpEF and obesity</dc:title>
<dc:identifier>pmid:37709935</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00935-6</dc:identifier>
</item>
<item>
<title>Immunomodulation and immunopharmacology in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37709934/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>The immune system is intimately involved in the pathophysiology of heart failure. However, it is currently underused as a therapeutic target in the clinical setting. Moreover, the development of novel immunomodulatory therapies and their investigation for the treatment of patients with heart failure are hampered by the fact that currently used, evidence-based treatments for heart failure exert multiple immunomodulatory effects. In this Review, we discuss current knowledge on how evidence-based...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 14. doi: 10.1038/s41569-023-00919-6. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The immune system is intimately involved in the pathophysiology of heart failure. However, it is currently underused as a therapeutic target in the clinical setting. Moreover, the development of novel immunomodulatory therapies and their investigation for the treatment of patients with heart failure are hampered by the fact that currently used, evidence-based treatments for heart failure exert multiple immunomodulatory effects. In this Review, we discuss current knowledge on how evidence-based treatments for heart failure affect the immune system in addition to their primary mechanism of action, both to inform practising physicians about these pleiotropic actions and to create a framework for the development and application of future immunomodulatory therapies. We also delineate which subpopulations of patients with heart failure might benefit from immunomodulatory treatments. Furthermore, we summarize completed and ongoing clinical trials that assess immunomodulatory treatments in heart failure and present several therapeutic targets that could be investigated in the future. Lastly, we provide future directions to leverage the immunomodulatory potential of existing treatments and to foster the investigation of novel immunomodulatory therapeutics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37709934/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37709934</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00919-6>10.1038/s41569-023-00919-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37709934</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>George Markousis-Mavrogenis</dc:creator>
<dc:creator>Lukas Baumhove</dc:creator>
<dc:creator>Ali A Al-Mubarak</dc:creator>
<dc:creator>Joseph Pierre Aboumsallem</dc:creator>
<dc:creator>Nils Bomer</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:date>2023-09-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Immunomodulation and immunopharmacology in heart failure</dc:title>
<dc:identifier>pmid:37709934</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00919-6</dc:identifier>
</item>
<item>
<title>Frataxin Deacetylation in Macrophages: Avoiding SIRTain Myocyte Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37708247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 15;133(7):648-650. doi: 10.1161/CIRCRESAHA.123.323503. Epub 2023 Sep 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37708247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37708247</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10506396/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">PMC10506396</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323503>10.1161/CIRCRESAHA.123.323503</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37708247</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Ronald J Vagnozzi</dc:creator>
<dc:creator>Emma L Robinson</dc:creator>
<dc:date>2023-09-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Frataxin Deacetylation in Macrophages: Avoiding SIRTain Myocyte Death</dc:title>
<dc:identifier>pmid:37708247</dc:identifier>
<dc:identifier>pmc:PMC10506396</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323503</dc:identifier>
</item>
<item>
<title>Resolving Proteotoxicity: Genetic Examination of Proteasome Activation by PKA In Vivo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37708246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 15;133(7):588-591. doi: 10.1161/CIRCRESAHA.123.323502. Epub 2023 Sep 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37708246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37708246</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323502>10.1161/CIRCRESAHA.123.323502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37708246</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Shirin Doroudgar</dc:creator>
<dc:date>2023-09-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Resolving Proteotoxicity: Genetic Examination of Proteasome Activation by PKA In Vivo</dc:title>
<dc:identifier>pmid:37708246</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323502</dc:identifier>
</item>
<item>
<title>α2δ-1 as a New Target for Immunosuppressant-Induced Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37708245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919021104&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 15;133(7):628-630. doi: 10.1161/CIRCRESAHA.123.323500. Epub 2023 Sep 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37708245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919021104&v=2.17.9.post6+86293ac">37708245</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323500>10.1161/CIRCRESAHA.123.323500</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37708245</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Antentor Hinton</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:date>2023-09-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>α2δ-1 as a New Target for Immunosuppressant-Induced Hypertension</dc:title>
<dc:identifier>pmid:37708245</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323500</dc:identifier>
</item>





























</channel>
</rss>